Conformational restriction leading to a selective CB2 cannabinoid receptor agonist orally active against colitis

ACS Medicinal Chemistry Letters

Volumn 6, Issue 2, 2015, Pages 198-203

  El Bakali, Jamal ^a,d   Muccioli, Giulio G ^b   Body Malapel, Mathilde ^c   Djouina, Madjid ^c   Klupsch, Frédérique ^a   Ghinet, Alina ^a   Barczyk, Amélie ^a   Renault, Nicolas ^a   Chavatte, Philippe ^a   Desreumaux, Pierre ^c   Lambert, Didier M ^b   Millet, Régis ^a  

^a Faculté des Sciences Pharmaceutiques et Biologiques Université de Lille   (France)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c UNIV LILLE   (France)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Cannabinoid receptor; colitis; conformational restriction; endocannabinoid; inflammatory bowel disease; quinolone

Indexed keywords

4 OXO 1,4 DIHYDROPYRIDINE; CANNABINOID 2 RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLITIS; CONTROLLED STUDY; DRUG CONFORMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; SURVIVAL RATE;

MUS;

EID: 84922855574     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml500439x     Document Type: Article

References (19)

1. Podolsky, D. K. Inflammatory Bowel Disease N. Engl. J. Med. 2002, 347, 417-429
2. Alhouayek, M.; Muccioli, G. G. The Endocannabinoid System in Inflammatory Bowel Diseases: From Pathophysiology to Therapeutic Opportunity Trends Mol. Med. 2012, 18, 615-25
3. Ihenetu, K.; Molleman, A.; Parsons, M. E.; Whelan, C. J. Inhibition of Interleukin-8 Release in the Human Colonic Epithelial Cell Line HT-29 by Cannabinoids Eur. J. Pharmacol. 2003, 458, 207-215
4. Kimball, E. S.; Schneider, C. R.; Wallace, N. H.; Hornby, P. J. Agonists of Cannabinoid Receptor 1 and 2 Inhibit Experimental Colitis Induced by Oil of Mustard and by Dextran Sulfate Sodium Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 291, 364-371
5. Storr, M. A.; Keenan, C. M.; Zhang, H.; Patel, K. D.; Makriyannis, A.; Sharkey, K. A. Activation of the Cannabinoid 2 Receptor (CB2) Protects Against Experimental Colitis Inflamm. Bowel Dis. 2009, 15, 1678-1685
6. Singh, U. P.; Singh, N. P.; Singh, B.; Price, R. L.; Nagarkatti, M.; Nagarkatti, P. S. Cannabinoid Receptor-2 (CB2) Agonist Ameliorates Colitis in IL-10(-/-) Mice by Attenuating the Activation of T Cells and Promoting their Apoptosis Toxicol. Appl. Pharmacol. 2012, 258, 256-267
7. El Bakali, J.; Gilleron, P.; Body-Malapel, M.; Mansouri, R.; Muccioli, G. G.; Djouina, M.; Barczyk, A.; Klupsch, F.; Andrzejak, V.; Lipka, E.; Furman, C.; Lambert, D. M.; Chavatte, P.; Desreumaux, P.; Millet, R. 4-Oxo-1,4-dihydropyridines as selective CB2 cannabinoid receptor ligands. Part 2: discovery of new agonists endowed with protective effect against experimental colitis J. Med. Chem. 2012, 55, 8948-8952
8. Tourteau, A.; Body-Malapel, M.; Andrzejak, V.; Lemaire, L.; Lemoine, A.; Mansouri, R.; El Bakali, J.; Desreumaux, P.; Muccioli, G. G.; Lambert, D. M.; Renault, N.; Chavatte, P.; Rigo, B.; Leleu-Chavain, N.; Millet, R. 3-Carboxamido-5-aryl-isoxazoles as new CB2 agonists for the treatment of colitis Bioorg. Med. Chem. 2013, 21, 5383-5394
9. Stern, E.; Muccioli, G. G.; Millet, R.; Goossens, J. F.; Farce, A.; Chavatte, P.; Poupaert, J. H.; Lambert, D. M.; Depreux, P.; Hénichart, J. P. Novel 4-Oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as New CB2 Cannabinoid Receptors Agonists: Synthesis, Pharmacological Properties and Molecular Modeling J. Med. Chem. 2006, 49, 70-79
10. Stern, E.; Muccioli, G. G.; Bosier, B.; Hamtiaux, L.; Millet, R.; Poupaert, J. H.; Hénichart, J. P.; Depreux, P.; Goossens, J. F.; Lambert, D. M. Pharmacomodulations Around the 4-Oxo-1,4-dihydroquinoline-3-carboxamides, a Class of Potent CB2-Selective Cannabinoid Receptor Ligands: Consequences in Receptor Affinity and Functionality J. Med. Chem. 2007, 50, 5471-5484
11. Graybill, T. L.; Dolle, R. E.; Osifo, I. K.; Schmidt, S. J.; Gregory, J. S.; Harris, A. L.; Miller, M. S. Inhibition of Human Erythrocyte Calpain I by Novel Quinolinecarboxamides Bioorg. Med. Chem. Lett. 1995, 5, 387-392
12. Wentland, M. P.; Perni, R. B.; Dorff, P. H.; Brundage, P.; Castaldi, M. J.; Bailey, T. R.; Carabateas, P. M.; Bacon, E. R.; Young, D. C.; Woods, M. G.; Rosi, D.; Drozd, M. L.; Kullnig, R. K.; Dutko, F. J. 3-Quinolinecarboxamides. A Series of Novel Orally-Active Antiherpetic Agents J. Med. Chem. 1993, 36, 1580-1596
13. Wentland, M. P.; Aldous, S. C.; Gruett, M. D.; Perni, R. B.; Powles, R. G.; Danz, D. W.; Klingbeil, K. M.; Peverly, A. D.; Robinson, R. G.; Corbett, T. H.; Rake, J. B.; Coughlin, S. A. The Antitumor Activity of Novel Pyrazoloquinoline Derivatives Bioorg. Med. Chem. Lett. 1995, 5, 405-410
14. Crespo, M. I.; Gràcia, J.; Puig, C.; Vega, A.; Bou, J.; Beleta, J.; Doménech, T.; Ryder, H.; Segarra, V.; Palacios, J. M. Synthesis and Biological Evaluation of 2,5-Dihydropyrazolo[4,3-c]quinolin-3-ones, a Novel Series of PDE 4 Inhibitors with Low Emetic Potential and Antiasthmatic Properties Bioorg. Med. Chem. Lett. 2000, 10, 2661-2664
15. Hayashi, H.; Miwa, Y.; Ichikawa, S.; Yoda, N.; Miki, I.; Ishii, A.; Kono, M.; Yasuzawa, T.; Suzuki, F. 5-HT3 receptor antagonists. 2. 4-hydroxy-3-quinolinecarboxylic acid derivatives J. Med. Chem. 1993, 36, 617-626
16. El Bakali, J.; Muccioli, G. G.; Renault, N.; Pradal, D.; Body-Malapel, M.; Djouina, M.; Hamtiaux, L.; Andrzejak, V.; Desreumaux, P.; Chavatte, P.; Lambert, D. M.; Millet, R. 4-Oxo-1,4-Dihydropyridines as Selective CB2 Cannabinoid Receptor Ligands: Structural Insights into the Design of a Novel Inverse Agonist Series J. Med. Chem. 2010, 53, 7918-7931
17. Manera, C.; Cascio, M. G.; Benetti, V.; Allarà, M.; Tuccinardi, T.; Martinelli, A.; Saccomanni, G.; Vivoli, E.; Ghelardini, C.; Di Marzo, V.; Ferrarini, P. L. New 1,8-Naphthyridine and Quinoline Derivatives as CB2 Selective Agonists Bioorg. Med. Chem. Lett. 2007, 17, 6505-6510
18. Renault, N.; Laurent, X.; Farce, A.; El Bakali, J.; Mansouri, R.; Gervois, P.; Millet, R.; Desreumaux, P.; Furman, C.; Chavatte, P. Virtual Screening of CB2 Receptor Agonists from Bayesian Network and High-Throughput Docking: Structural Insights into Agonist-Modulated GPCR Features Chem. Biol. Drug Des. 2013, 81, 442-454
19. Desreumaux, P.; Dubuquoy, L.; Nutten, S.; Peuchmaur, M.; Englaro, W.; Schoonjans, K.; Derijard, B.; Desvergne, B.; Wahli, W.; Chambon, P.; Leibowitz, M. D.; Colombel, J. F.; Auwerx, J. Attenuation of Colon Inflammation Through Activators of the Retinoid X Receptor (RXR)/Peroxisome Proliferator-Activated Receptor Gamma (PPARgamma) Heterodimer. A Basis for New Therapeutic Strategies J. Exp. Med. 2001, 193, 827-838